Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.

NCT ID: NCT04644822

Last Updated: 2024-02-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-21
• Study Completion Date: 2024-01-08

Brief Summary

This is a prospective, Phase 3 non-randomized, open label, multi-centre clinical trial to assess the safety and efficacy of [18F]PSMA-1007 Injection (investigational product or IP) in evaluating men with suspected persistent or recurrent disease (i.e., with biochemical failure), but with negative or equivocal conventional re-staging imaging (bone scan [BS] and computed tomography [CT] of abdomen and pelvis).

Conditions

Prostate Cancer Recurrent; Recurrent Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

[18F]PSMA-1007 Injection

A single dose of 3 - 4 MBq/kg Body Weight (up to a maximum of 400 MBq) of \[18F\]PSMA-1007 Injection will be administered followed by PET/CT imaging. (Patients on ADT treatment will receive the second dose approximately 6 months after the first dose)

Group Type: EXPERIMENTAL

[18F] PSMA-1007 Injection

Intervention Type: DIAGNOSTIC_TEST

a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.

Interventions

[18F] PSMA-1007 Injection

a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

1. Able to read and speak in English and provide informed consent

2. Male, Age ≥ 18 years

3. Prior primary treatment for prostate cancer with curative intent such as radical prostatectomy or radiotherapy for localized prostate cancer or other local or focal ablative therapy of the prostate

4. Not currently on systemic therapy (adjuvant or salvage) including androgen deprivation therapy

5. Suspected progressive or persistent disease after primary treatment for prostate cancer and biochemical failure (BF) with current management according to the following:

1. Following primary radical prostatectomy (with or without adjuvant or salvage radiotherapy to the prostate bed/pelvis), where BF is defined as rising PSA on at least 2 occasions measured at least 1 month apart and with the most recent PSA measured within 3 months prior to enrollment at > 0.1 ng/mL

2. Following primary radiotherapy (with either brachytherapy, external beam radiotherapy or combined brachytherapy and radiotherapy) for localized disease, where BF is defined according to the Phoenix Definition, which is rising PSA on at least 2 occasions measured at least 1 month apart and with the most recent PSA measured within 3 months prior to enrollment greater than the nadir PSA + 2.0 ng/mL

3. Following primary ablative therapy to the prostate given with radical intent such as prior HIFU (high intensity focused ultrasound) or cryotherapy or other ablative energy therapy with biochemical failure as defined by the Stuttgart Criteria (nadir PSA + 1.2 ng/mL within 3 months prior to enrollment )

6. If PSA > 10 ng/mL, conventional imaging consisting of bone scan and CT scan within 3 months prior to consent that is either negative or equivocal.

7. Male subjects must be either:

1. Documented by medical records or physician's note to be surgically sterile or,

2. If capable of fathering a child, commit to the use of a barrier method of contraception, or agree to remain abstinent for 48 hours post-administration of the IP

8. Male subjects must agree to not donate sperm for 48 hours post-administration of the IP

9. Willing to participate in the study, is expected to be compliant, able to cooperate with study procedures, and have a high probability of completing the study in the opinion of the investigator

10. Vital sign results at Visit 1 and (pre-IP administration) at Visit 2 are within normal ranges, or if outside the normal ranges the results are judged by the investigator to not be clinically significant

11. Karnofsky performance status 70 or better (ECOG 0, 1)

12. Life expectancy of 6 months or more as judged by the investigator

13. Patient is medically suitable for salvage therapies

Exclusion Criteria

1. Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components

2. Prior PSMA PET scan within 6 months of enrolment

3. Use of any other investigational medication or devices within 30 days prior to Visit 1

4. Known allergies or sensitivity to any component of the investigational product used in this study

5. Received significant ionizing radiation exposure, as judged by the Investigator, including from diagnostic or therapeutic radiopharmaceuticals used in clinical trials or for routine medical examinations, in the last 12 months

6. Undergoing ongoing occupational monitoring for radiation exposure

7. Clinically active, unstable, serious, life-threatening medical condition or disease that is, in the opinion of the Investigator, inadequately treated and/or where study participation may compromise the clinical management of the subject, or any other reason that makes the subject unsuitable to participate in this study

8. The participant has a history of alcohol or substance abuse

9. Patient cannot lie still for at least 30 minutes or comply with imaging procedure

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

McDougall Scientific Ltd.

UNKNOWN

Sponsor Role: collaborator

Centre for Probe Development and Commercialization

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

London Health Sciences Centre

London, Ontario, Canada

University Health Network - Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

CPD-002

Identifier Type: -

Identifier Source: org_study_id